Understanding the Pathology of Gastroesophageal Reflux Disease (GERD)
Acid peptic disorders (APD), non-ulcer dyspepsia, and chronic GERD are among the most frequent clinical presentations in daily outpatient departments (OPDs). Lifestyle changes, irregular meal timings, and stress exacerbate gastric hyperacidity and delayed gastric emptying.
Why Esomeprazole is the Preferred S-Isomer Proton Pump Inhibitor
Esomeprazole, the pure (S)-isomer of omeprazole, offers significant pharmacodynamic advantages over racemic PPIs:
- Higher Bioavailability: Slower metabolic clearance through CYP2C19 resulting in higher and more sustained plasma concentrations.
- Superior 24-Hour Intragiastric pH Control: Maintains intragastric pH > 4 for significantly longer hours per day.
- Faster Mucosal Healing: Accelerates healing rates in erosive esophagitis and duodenal ulcers.
Synergy with Prokinetic Agents: Domperidone & Itopride
While PPIs suppress acid secretion, co-existing motility dysfunction requires prokinetic support:
- Esomeprazole + Domperidone (SHIKPRAZ-D): Domperidone provides dopamine D2 receptor antagonism, enhancing lower esophageal sphincter tone and accelerating gastric emptying.
- Esomeprazole + Itopride (SHIKPRAZ-IT): Itopride combines dual action (D2 receptor antagonism + acetylcholinesterase inhibition) without cardiac QT-interval risks, making it the ideal choice for chronic functional dyspepsia.
Explore our complete gastro and digestive range in the Shikoy Pharma Products Catalog.